Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer.

CONCLUSION: Our data supports the use of 60 mg/m(2) Q3W docetaxel which has similar efficacy and an acceptable toxicity profile compared to the standard 75 mg/m(2) Q3W regimen. Weekly docetaxel has significant palliative benefits among symptomatic patients despite lower overall survival.
PMID: 28600580 [PubMed - in process]

Source: Annals of the Academy of Medicine, Singapore - May 1, 2017 Category: General Medicine Authors: Ang JW, Tan MH, Tay MH, Toh CK, Ng QS, Kanesvaran R Tags: Ann Acad Med Singapore Source Type: research